Importer of Controlled Substances; Notice of Application, 6578-6579 [E7-2328]
Download as PDF
<![CDATA[
6578
Federal Register / Vol. 72, No. 28 / Monday, February 12, 2007 / Notices
STATS ChipPAC Ltd., Singapore,
Singapore; Supresta, Ardsley, NY; and
UGS Corporation, Milford, OH have
been added as parties to this venture.
Also, Heraeus, Inc., West
Conshohocken, PA; Total Parts Plus,
Fort Walton Beach, FL; and Nortel,
Toronto, Ontario, CANADA have
withdrawn as parties to this venture. In
addition, Alcatel and Lucent
Technologies have merged with the
name of the combined companies
changed to Alcatel-Lucent, Paris,
France.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and iNEMI
intends to file additional written
notifications disclosing all changes in
membership.
On June 6, 1996, iNEMI filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 28, 1996 (61 FR 33774).
The last notification was filed with
the Department on January 5, 2006. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on February 8, 2006 (71 FR 6522).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–604 Filed 2–9–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Antitrust Division
sroberts on PROD1PC70 with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Spray Drift Task Force
Notice is hereby given that, on
December 29, 2006, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’), Spray
Drift Task Force (‘‘SDTF’’) has filed
written notifications simultaneously
with the Attorney General and the
Federal Trade Commission disclosing
changes in its membership. The
notifications were filed for the purpose
of extending the Act’s provisions
limiting the recovery of the antitrust
plaintiffs to actual damages under
specified circumstances. Specifically,
AgValue Enterprises, Inc., Visalia, CA
joined SDTF and was subsequently
acquired by United Phosphorous, Inc.,
Trenton, NJ. Also, the membership
formerly owned by AgValue Enterprises,
Inc., Visalia, CA, but acquired by United
VerDate Aug<31>2005
19:52 Feb 09, 2007
Jkt 211001
Phosphorous, Inc., Trenton, NJ, was
transferred to Etigra, LLC, Cary, NC. The
membership formerly held by Griffin
Corporation, Valdosta, GA, but acquired
by E.I. duPont de Nemours and
Company, Newark, DE, was transferred
to Mitsui Chemicals, Tokyo, Japan. The
membership formerly held by Alsan
Research, Ankeny, IA, but acquired by
Dow AgroSciences LLC, Indianapolis,
IN, was transferred to Isagro,
Morrisville, NC. The membership
formerly held by Nations Ag II, LLC,
Knoxville, TN, but acquired by
Makhteshim-Agan of North America,
Inc., Raleigh, NC, was transferred to
Zhejiang Tide Crop Science Co., Ltd.,
Hangzhou, People’s Republic of China.
Futhermore, UCB Chemicals
Corporation, Gent, Belgium transferred
its membership to Taminco, Inc., Gent,
Belgium. Also, Arvesta Corporation, San
Francisco, CA changed its name to
Arysta LifeScience North America
Corporation, and relocated to Cary, NC;
Crompton Corporation, Bethany, CT
changed its name to Chemtura
Corporation; and Chimac-Agriphar SA,
Ougree, Belgium changed its name to
Agriphar SA.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and SDTF intends
to file additional written notifications
disclosing all changes in membership.
On May 15, 1990, SDTF filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on July 5, 1990 (55 FR 27701).
The last notification was filed with
the Department on August 25, 2003. A
notice was published in the Federal
Register pursuant to section 6(b) of the
Act on September 26, 2003 (68 FR
55657).
Patricia A. Brink,
Deputy Director of Operations, Antitrust
Division.
[FR Doc. 07–606 Filed 2–9–07; 8:45 am]
BILLING CODE 4410–11–M
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on November 22,
2006, Cambrex Charles City, Inc., 1205
11th Street, Charles City, Iowa 50616,
made application by renewal to the
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
Drug Enforcement Administration
(DEA) as a bulk manufacturer of the
basic classes of controlled substances
listed in schedule II:
Drug
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Phenylacetone (8501) ..................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Fentanyl (9801) ............................
Schedule
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sales to its customers.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than April 13, 2007.
Dated: February 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–2317 Filed 2–9–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on October
31, 2006, Fisher Clinical Services Inc.,
7554 Schantz Road, Allentown,
Pennsylvania 18106, made application
by letter to the Drug Enforcement
E:\FR\FM\12FEN1.SGM
12FEN1
6579
Federal Register / Vol. 72, No. 28 / Monday, February 12, 2007 / Notices
Administration (DEA) to be registered as
an importer of Noroxymorphone (9668),
a basic class of controlled substance
listed in schedule II.
The company plans to import the
listed substance for analytical research
and clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than March 14, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: February 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–2328 Filed 2–9–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
sroberts on PROD1PC70 with NOTICES
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
VerDate Aug<31>2005
19:52 Feb 09, 2007
Jkt 211001
bulk manufacturer of a controlled
substance in schedule I or II and prior
to issuing a regulation under 21 U.S.C.
952(a)(2)(B) authorizing the importation
of such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on
December 14, 2006, Mallinckrodt Inc.,
3600 North Second Street, St. Louis,
Missouri 63147, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
Drug
Schedule
Phenylacetone (8501) ..................
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw (9650) .....................
Poppy Straw Concentrate (9670)
II
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of controlled substances in
bulk for distribution to its customers.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, D.C. 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than March 14, 2007.
This procedure is to be conducted
simultaneously with and independent
of the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: February 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E7–2326 Filed 2–9–07; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on December 12, 2006,
Orasure Technologies, Inc., Lehigh
University, Seeley G Mudd-Building 6,
220 East First Street, Bethlehem,
Pennsylvania 18015, made application
by renewal to the Drug Enforcement
Administration (DEA) as a bulk
manufacturer of the basic classes of
controlled substances listed in schedule
I and II:
Drug
Lysergic acid diethylamide (LSD)
(7315).
4–Methoxyamphetamine (7411) ...
Normorphine (9313) .....................
Tetrahydrocannabinols
(THC)
(7370).
Alphamethadol (9605) ..................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Cocaine (9041) .............................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Hydrocodone (9193) .....................
Morphine (9300) ...........................
Oxycodone (9143) ........................
Meperidine (9230) ........................
Methadone (9250) ........................
Oxymorphone (9652) ...................
Schedule
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
to manufacture controlled substance
derivatives. These derivatives will be
used in diagnostic products created
specifically for internal use only.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
E:\FR\FM\12FEN1.SGM
12FEN1
]]>Agencies
[Federal Register Volume 72, Number 28 (Monday, February 12, 2007)]
[Notices]
[Pages 6578-6579]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-2328]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II and prior to issuing a
regulation under 21 U.S.C. 952(a)(2)(B) authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on October 31, 2006, Fisher Clinical Services Inc., 7554 Schantz
Road, Allentown, Pennsylvania 18106, made application by letter to the
Drug Enforcement
[[Page 6579]]
Administration (DEA) to be registered as an importer of Noroxymorphone
(9668), a basic class of controlled substance listed in schedule II.
The company plans to import the listed substance for analytical
research and clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic class of controlled
substance may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43 and in
such form as prescribed by 21 CFR 1316.47.
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than March 14, 2007.
This procedure is to be conducted simultaneously with and
independent of the procedures described in 21 CFR 1301.34(b), (c), (d),
(e) and (f). As noted in a previous notice published in the Federal
Register on September 23, 1975, (40 FR 43745-46), all applicants for
registration to import a basic class of any controlled substance listed
in schedule I or II are, and will continue to be required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and
21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied.
Dated: February 5, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E7-2328 Filed 2-9-07; 8:45 am]
BILLING CODE 4410-09-P
